Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Cancer Res. 2018 Nov 2;79(1):209–219. doi: 10.1158/0008-5472.CAN-18-0717

Fig. 6:

Fig. 6:

PP2A activation combined with mTOR inhibition as a therapeutic strategy to reduce PDA survival. A. Oncogenic KRAS drives the activation of both the MYC and PI3K/AKT/mTOR pathways. Upon mTOR inhibition, PDA cells capitalize on low PP2A levels, signaling through MYC for survival, creating a MYCHigh/mTORLow cell state. B. Activation of PP2A combined with mTOR inhibition results in low MYC and mTOR signaling in a MYCLow/mTORLow cell state, decreasing PDA cell survival.